Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Nassim Nabbout (NPI 1528029147)

Field	Value
Entity Type	Individual
Organization	Nassim Nabbout
Address	3243 E Murdock St
City	Wichita
State	KS
ZIP	67208
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 31, 2006

Payer Source	Total Paid
Medicare	$4.2M
Medicaid	$0

Key Findings

Total Medicare revenue for this Hematology & Oncology Physician in Wichita, KS is $4.2M while there is no Medicaid billing on file, indicating an effectively single‑payer (Medicare-focused) billing profile. The provider’s NPI was enumerated 2006-03-31 (~20 years ago), consistent with an established practice operating in the Medicare space.

Revenue is highly concentrated in a small set of high-cost oncology drugs: the precomputed top 3 Medicare codes (J9271, J9299, J9145) account for 58.0% of this provider’s total Medicare revenue. Specifically, J9271 accounts for $1.2M (29.4%), J9299 for $819.8K (20.6%), and J9145 for $316.8K (8.0%), underscoring that checkpoint inhibitors and targeted monoclonal therapies drive the business.

The code mix indicates an infusion-centric oncology practice focused on immunotherapy and monoclonal antibody treatments: high-revenue entries include J9271 (pembrolizumab), J9299 (nivolumab), J9022 (atezolizumab), and daratumumab entries J9145 and J9144. In addition, typical chemotherapy administration codes (96413, 96401) and infusion administration codes (96367) appear in the top volume list, showing the practice combines procedural infusion services with high-cost drug delivery.

Competitive standing for the top immunotherapy drugs is mixed: J9271 ranks #171 of 1841 nationally (90th percentile; typical, unremarkable volume) and J9299 ranks #54 of 505 (89th percentile; typical, unremarkable volume), indicating above‑median national volumes but characterized as within typical ranges for these codes. By contrast, J9145 ranks #9 of 14 (38th percentile; typical, unremarkable volume), so the provider is not a leading national outlier for all top biologics and appears to be a strong but not dominant national participant for PD‑1 inhibitor therapies.

Several administration and supportive-care codes are statistical outliers relative to peers: 96413 is labeled an "extreme outlier, far above typical national volume" (873 claims, $82.1K revenue), while 96367 (820 claims, $17.2K) and 99213 (706 claims, $43.1K) are described as "notably above typical national volume." These high relative ranks for infusion and evaluation codes suggest the practice delivers a higher-than-typical throughput of infusion visits and concurrent clinic evaluation activity.

The practice also shows very high volumes of many low‑paid, supportive or ancillary injectable items: for example, J1439 appears with 56.3K claims and $56.3K revenue (1.4%), and J1627 has 15.4K claims for $77K revenue (1.9%). This pattern—large claim counts at low average paid/claim—signals routine administration of supportive medications and frequent dosing events alongside the higher-value oncology agents.

E/M coding and new patient visits are present but represent a small share of revenue, consistent with an infusion-forward business model that retains some ambulatory clinic activity: 99214 appears with 595 claims and $54.1K revenue (1.4%), 99213 with 706 claims and $43.1K revenue (1.1%), and 99205 with 92 claims and $14K revenue (0.4%). The mix indicates ongoing outpatient management and new patient intake co‑located with infusion services rather than a visit‑only practice.

From a payer and market perspective, the absence of Medicaid billing on file combined with concentrated Medicare revenue around high-cost oncology biologics positions this provider as an established, Medicare-focused oncology infusion practice in Wichita. The ~20-year NPI tenure supports an entrenched local presence, and national percentile ranks show above-median activity for several immunotherapy agents while remaining within the typical volume band for many codes, implying competitiveness without clear national dominance.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

100 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	27,200	$40	$1.2M
J9299	Injection, nivolumab, 1 mg	34,160	$20	$819.8K
J9145	Injection, daratumumab, 10 mg	6,740	$50	$316.8K
J9022	Injection, atezolizumab, 10 mg	4,580	$60	$293.4K
J0897	Injection, denosumab, 1 mg	12,720	$20	$241.7K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	12,000	$10	$120K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	3,060	$40	$119.3K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,250	$30	$110.5K
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	1,350	$60	$85K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	870	$90	$82.1K

Showing 1–10 of 100

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 100 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Nassim Nabbout — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

100 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	12	20	28,900	$40	$1.1M
J9299	4	10	24,550	$20	$637.2K
J9145	5	10	6,660	$50	$394.7K
J9022	3	10	3,910	$60	$301.1K
J9144	8	10	6,300	$40	$257.2K
J1568	9	10	3,690	$30	$129K
Q5107	9	10	4,440	$20	$106.5K
Q5115	9	10	2,340	$30	$92.9K
J9264	2	10	6,930	$10	$89.7K
J0897	14	180	2,160	$20	$81.5K

Showing 1–10 of 100

Related Providers

Other providers that share a Tax Identification Number (TIN) with Nassim Nabbout, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Nassim Nabbout, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ascension Medical Group Via Christi, PA	KS	Multi-Specialty Clinic/Center	$0	$21.2M
County Of Sedgwick	KS	Case Manager/Care Coordinator	$0	$15.5M
County Of Sedgwick	KS	Psychiatry Physician	$0	$5.9M
Great Plains Dental Group, LLC	KS	General Practice Dentistry	$0	$5.8M
Mental Health America Of South Central Kansas, Inc.	KS	Community/Behavioral Health Agency	$0	$5.7M
Kidspace Pediatric Dentistry,p.a	KS	Pediatric Dentistry	$0	$4.4M
Cerebral Palsy Research Foundation Of Kansas, Inc	KS	Non-emergency Medical Transport (VAN)	$0	$4.3M
Phu Truong	KS	Hematology & Oncology Physician	$4.1M	$0
Grace Home Care, LLC	KS	Home Health Agency	$0	$4M
Joseph Moore	KS	Hematology & Oncology Physician	$3.6M	$0

Nassim Nabbout — Billing Profile & Reimbursement Data

Sign up for Nassim Nabbout — Billing Profile & Reimbursement Data policy alerts

Nassim Nabbout — Billing Profile & Reimbursement Data

Sign up for Nassim Nabbout — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References